Beigene has quickly become a force in cancer drug development, earning approvals in the U.S. and China for its targeted therapy Brukinsa and immunotherapy tislelizumab. The biotech is developing a slate of small molecule and antibody drugs aimed at several well-known targets, too.
In late 2019, Amgen agreed to pay nearly $3 billion for a 20% stake in Beigene. Notably, Beigene agreed to help Amgen develop as many as 20 experimental drugs and chip in funding as well, a sign of Amgen’s confidence in the company’s research skills.
So far, all of the drugs Beigene has advanced into clinical testing have been small molecules or antibodies. The Shoreline deal will expand the company’s work to include cell therapy, an area that’s growing quickly to encompass multiple types of treatment and technologies. READ MORE
By Ned Pagliarulo
NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.
The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.
BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.